Premium
Antimicrobial‐resistant Escherichia coli in hospitalised companion animals and their hospital environment
Author(s) -
Tuerena I.,
Williams N. J.,
Nuttall T.,
Pinchbeck G.
Publication year - 2016
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/jsap.12525
Subject(s) - escherichia coli , antimicrobial , microbiology and biotechnology , antibiotic resistance , medicine , drug resistance , feces , beta lactamase , antimicrobial stewardship , antibiotics , veterinary medicine , biology , gene , genetics
Introduction Antimicrobial resistance is a growing concern with implications for animal health. This study investigated the prevalence of antimicrobial resistance among commensal and environmental Escherichia coli isolated from animals sampled in referral hospitals in the UK . Materials and Methods Resistant Escherichia coli isolated from animal faeces and practice environments were tested for susceptibility to antimicrobial agents. PCR and sequencing techniques were used to identify extended spectrum beta‐lactamase and AmpC ‐producer genotypes. Results In total, 333 faecal and 257 environmental samples were collected. Multi‐drug resistant Escherichia coli were found in 13·1% of faecal and 8·9% of environmental samples. Extended spectrum beta‐lactamase and AmpC genes were identified 14% and 7·7% of faecal samples and 8·6% and 8·6% of environmental samples, respectively. The most common extended spectrum beta‐lactamase gene type detected was bla CTX‐M −15 , although bla TEM‐158 was detected in faecal and environmental samples from one practice. Clinical Significance Escherichia coli resistant to key antimicrobials were isolated from hospitalised animals and the practice environment. We identified the emergence of the inhibitor resistant and extended spectrum beta‐lactamase bla TEM‐158 in companion animals. Further investigation to determine risk factors for colonisation with antimicrobial‐resistant bacteria is needed to provide evidence for antimicrobial stewardship and infection control programmes.